Hepatitis B virus vaccine. An analysis of its potential use in medical workers.

Published

Journal Article

At the Duke University Medical Center, Durham, NC, there are approximately ten recognized hepatitis B virus (HBV) infections per year in employees. The hospital's hepatitis control program costs $91,995 per year, including costs for workman's compensation, hyperimmune globulin, laboratory tests, lost revenue, liability, personnel, and medical treatment. A program to immunize high-risk medical center personnel and to accommodate residual HBV problems in nonimmunized employees would cost $206,304 in the first year. By seven years the cumulative costs of an immunization program would equal those without a program and at ten years would be cost saving ($746,742 with program v $919,950 without a program). Given certain assumptions, HBV vaccine is a cost-beneficial alternative for a major employee health hazard.

Full Text

Duke Authors

Cited Authors

  • Hamilton, JD

Published Date

  • October 28, 1983

Published In

Volume / Issue

  • 250 / 16

Start / End Page

  • 2145 - 2150

PubMed ID

  • 6413707

Pubmed Central ID

  • 6413707

International Standard Serial Number (ISSN)

  • 0098-7484

Digital Object Identifier (DOI)

  • 10.1001/jama.250.16.2145

Language

  • eng

Conference Location

  • United States